Unraveling hcv pathogenicity for the preclinical development of new therapeutic strategies (HEPCVAX)

Objective

The overall objectives of the HepCVax cluster is to identify viral and host mechanisms which are involved in
(I) viral replication and particle formation,
(ii) pathogen city and viral persistence and, based on the knowledge of virus properties as well as virus-host interactions and pathogenesis,
(iii) to identify innovative antiviral and immunotherapeutic strategies capable of inducing a broad and sustained HCV specific cellular-mediated immune responses. All information emerging from the understanding of the HCV genome will be integrated in the first ever-European sequence database dedicated to Hepatitis C virus. The cluster will be subdivided in three component Networks. Whereas HepCVax-PARTIC will concentrate on the molecular and intracellular level of the virus-host interactions through the identification of factors involved in HCV-particles formation, HepCVax.IMPA TH will focus on the interaction between HCV and different arms of the innate and adaptive immune response. HepCVax-PRECLIN will exploit the expected discoveries made by Networks 1 and 2 to develop and test new immunotherapeutic strategies in vitro and in small animal models.

Fields of science

• natural sciences › computer and information sciences › databases
• natural sciences › biological sciences › microbiology › virology
• medical and health sciences › health sciences › infectious diseases › RNA viruses › hepatitis C
• medical and health sciences › basic medicine › immunology
• natural sciences › biological sciences › genetics › genomes

Programme(s)

• FP5-LIFE QUALITY - Specific Programme for research, technological development and demonstration on "Quality of life and management of living resources", 1998-2002

Topic(s)

• 1.1.1.-2. - Key action Control of Infectious Diseases

Call for proposal

Data not available

Funding Scheme

CSC - Cost-sharing contracts

Coordinator

LEIDEN UNIVERSITY

Address

Albinusdreef 2
2300 RC Leiden
Netherlands

Participants (15)

ALBERT-LUDWIGS-UNIVERSITAET FREIBURG

Germany

Address

Hugstetterstr. 55
79106 Freiburg (In Breisgau)

BIOMERIEUX SA

France

Address

Cervi - 21, Av. Tony Garnier
69365 Lyon

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

France

Address

Rue Du Professeur Calmette 1
59021 Lille

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

France

Address

Allte D'italie 46
69364 Lyon

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

France

Address

7,passage Du Vercors 7
69367 Lyon

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

France

Address

Rue Koeberle 3 Adr 16 - Alsace
67000 Strasbourg

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

France

Address

46, Allee D'italie
69634 Venissieux

LUDWIG-MAXIMILIANS UNIVERSITY OF MUNICH

Germany

Address

Marchioninistr. 15
81377 Muenchen

PEVION BIOTECH AG

Switzerland

Address

Rehhagstrasse 79
3018 Bern

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD

United Kingdom

Address

John Radcliffe Hospital - Oxfordshire 5802
OX3 9DU Oxford/headington

UNIVERSITA DEGLI STUDI DI BARI

Italy

Address

Piazza Umberto I Palazzo Ateneo 1
70121 Bari

UNIVERSITAETSKLINIKUM HEIDELBERG

Germany

Address

Otto-meyerhof-zentrum, Im Neuenheimer Feld 324
69120 Heidelberg

UNIVERSITE CLAUDE BERNARD LYON 1

France

Address

Passage Du Vercors 7
69367 Lyon

UNIVERSITE DE PARIS V 'RENÉ DESCARTES'

France

Address

156,rue De Vaugirard 156, Chu Necker
75730 Paris

UNIVERSITY OF BERNE

Switzerland

Address

49,murtenstrasse 35
3010 Bern